Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transcendence A: Pegylated interferon α-2β after radical resection of hepatitis B-related hepatocellular carcinoma
ChiCTR2600126158Phase 4Recruiting
- Sponsor
- Ningbo No. 2 Hospital
- Start
- Jun 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in hepatocellular carcinoma (HCC) and Chronic Hepatitis B (CHB) (2 arms), sponsored by Ningbo No. 2 Hospital. Primary endpoints: HBsAg level, HBsAg seroconversion rate and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2600126158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126158.